scholarly journals Cell Ratio Differences in Peripheral Blood between Early- and Late-Onset Parkinson’s Disease: A Case-Control Study

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
Sen Jiang ◽  
Yuling Wang ◽  
Hua Gao ◽  
Qin Luo ◽  
Dan Wang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Roc Curve ◽  
Late Onset ◽  
Diagnostic Value ◽  
Curve Analysis ◽  
Onset Age ◽  
Immune Disorders ◽  
Roc Curve Analysis ◽  
Cell Ratio

Objectives. To explore the differences of immune disorders in peripheral blood between patients with early-onset Parkinson’s disease (EOPD) and late-onset Parkinson’s disease (LOPD). Methods. We retrospectively reviewed medical records of Parkinson’s disease (PD) patients and healthy controls between June 2002 and July 2017. At last, we included 117 PD patients who were divided into EOPD and LOPD according to whether onset age of PD was after 50 and 99 controls divided into E-Control (match for EOPD) and L-Control (match for LOPD) according to whether their age was after 53 which was onset age plus median of disease duration. We compared the ratios of cells between multiple groups and performed the multinominal logistic regression analysis to explore the relationship between ratios and subtypes of PD. We also carried out the receiver operating characteristic (ROC) curve analysis to estimate the diagnostic value of the variable. Results. Lymphocyte-red blood cell ratio (LRR) was lower in LOPD compared with that in EOPD or L-Control. LRR was also negatively associated with LOPD (OR: 0.623; 95% CI: 0.397–0.980; P=0.040). The ROC curve analysis showed the optimal cutoff value of 4.53 (×10−4) of LRR for discrimination of LOPD versus L-Control (sensitivity: 0.596, specificity: 0.764). The area under curve (AUC) was 0.721. As for LOPD versus EOPD, the optimal threshold of LRR was 4.10 (×10−4) (sensitivity: 0.516, specificity: 0.745). AUC was 0.641. Conclusions. Peripheral immune disorders might play an important part in the pathological progression of LOPD. Also, LRR has potential diagnostic value.

scholarly journals Gene4PD: A Comprehensive Genetic Database of Parkinson’s Disease

2021 ◽  
Vol 15 ◽  
Author(s):  
Bin Li ◽  
Guihu Zhao ◽  
Qiao Zhou ◽  
Yali Xie ◽  
Zheng Wang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorder ◽  
Late Onset ◽  
Association Studies ◽  
Age At Onset ◽  
Genetic Data ◽  
Genome Wide Association Studies ◽  
Onset Age ◽  
Loss Of Function

Parkinson’s disease (PD) is a complex neurodegenerative disorder with a strong genetic component. A growing number of variants and genes have been reported to be associated with PD; however, there is no database that integrate different type of genetic data, and support analyzing of PD-associated genes (PAGs). By systematic review and curation of multiple lines of public studies, we integrate multiple layers of genetic data (rare variants and copy-number variants identified from patients with PD, associated variants identified from genome-wide association studies, differentially expressed genes, and differential DNA methylation genes) and age at onset in PD. We integrated five layers of genetic data (8302 terms) with different levels of evidences from more than 3,000 studies and prioritized 124 PAGs with strong or suggestive evidences. These PAGs were identified to be significantly interacted with each other and formed an interconnected functional network enriched in several functional pathways involved in PD, suggesting these genes may contribute to the pathogenesis of PD. Furthermore, we identified 10 genes were associated with a juvenile-onset (age ≤ 30 years), 11 genes were associated with an early-onset (age of 30–50 years), whereas another 10 genes were associated with a late-onset (age > 50 years). Notably, the AAOs of patients with loss of function variants in five genes were significantly lower than that of patients with deleterious missense variants, while patients with VPS13C (P = 0.01) was opposite. Finally, we developed an online database named Gene4PD (http://genemed.tech/gene4pd) which integrated published genetic data in PD, the PAGs, and 63 popular genomic data sources, as well as an online pipeline for prioritize risk variants in PD. In conclusion, Gene4PD provides researchers and clinicians comprehensive genetic knowledge and analytic platform for PD, and would also improve the understanding of pathogenesis in PD.

scholarly journals Circulating Inflammatory miRNAs Associated with Parkinson’s Disease Pathophysiology

Biomolecules ◽  
2020 ◽  
Vol 10 (6) ◽  
pp. 945 ◽  
Author(s):  
Sara R. Oliveira ◽  
Pedro A. Dionísio ◽  
Leonor Correia Guedes ◽  
Nilza Gonçalves ◽  
Miguel Coelho ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Roc Curve ◽  
Operating Characteristic ◽  
Disease Diagnosis ◽  
Healthy Controls ◽  
Roc Curve Analysis ◽  
Additional Group ◽  
Lrrk2 Gene ◽  
Non Coding Rnas

Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide, being largely characterized by motor features. MicroRNAs (miRNAs) are small non-coding RNAs, whose deregulation has been associated with neurodegeneration in PD. In this study, miRNAs targeting cell death and/or inflammation pathways were selected and their expression compared in the serum of PD patients and healthy controls. We used two independent cohorts (discovery and validation) of 20 idiopathic PD patients (iPD) and 20 healthy controls each. We also analyzed an additional group of 45 patients with a mutation in the leucine-rich repeat kinase 2 (LRRK2) gene (LRRK2-PD). miRNA expression was determined using Taqman qRT-PCR and their performance to discriminate between groups was assessed by receiver operating characteristic (ROC) curve analysis. We found miR-146a, miR-335-3p, and miR-335-5p downregulated in iPD and LRRK2-PD patients versus controls in both cohorts. In addition, miR-155 was upregulated in LRRK2-PD compared to iPD patients showing an appropriate value of area under the ROC curve (AUC 0.80) to discriminate between the two groups. In conclusion, our study identified a panel of inflammatory related miRNAs differentially expressed between PD patients and healthy controls that highlight key pathophysiological processes and may contribute to improve disease diagnosis.

scholarly journals Prediction of nerve block success using ultrasonographic parameters: A preliminary animal study

2021 ◽  
Author(s):  
Emiko Chiba ◽  
Kohei Hamamoto ◽  
Eiichi Kanai ◽  
Noriko Oyama-Manabe ◽  
Kiyoka Omoto
Keyword(s):  
Sciatic Nerve ◽  
Diagnostic Accuracy ◽  
Nerve Block ◽  
Roc Curve ◽  
Diagnostic Value ◽  
Curve Analysis ◽  
Block Group ◽  
Roc Curve Analysis ◽  
Biceps Femoris Muscle ◽  
Block Success

Abstract This study aimed to evaluate the diagnostic value of ultrasonographic parameters as an indicator for predicting regional nerve block success. Ultrasound-guided sciatic nerve block was performed in seven dogs using either 2% mepivacaine (nerve-block group) or saline (sham-block group). The cross-sectional area (CSA), nerve blood flow (NBF), and shear wave velocity (SWV) of the sciatic nerve (SWVN), SWV of the biceps femoris muscle (SWVM), and their ratio (SWVNMR) were measured at 0, 30, 60, and 90 min after the nerve block as well as the change rate of each parameter from the baseline. A receiver operating characteristic (ROC) curve analysis was performed to determine the diagnostic value of each parameter in the prediction of nerve block success. No significant changes were observed in the CSA or NBF in association with the nerve block. The SWVN and SWVNMR in the nerve-block group were significantly higher than those in the sham-block group at 90 min and at 30, 60, and 90 min, respectively (p < 0.05). The change rates of SWVN and SWVNMR in the nerve-block group were significantly higher than those in the sham-block group at all time points (p < 0.05). The ROC curve analysis showed that SWVN had a moderate diagnostic accuracy (area under the curve [AUC], 0.779), whereas SWVNMR and change rates of SWVN and SWVNMR had a high diagnostic accuracy (AUC, 0.947, 0.998, and 1.000, respectively). Ultrasonographic evaluation of the SWVN and SWVNMR could be used as indicators for predicting nerve block success.

scholarly journals Downregulation of lncRNA-PVT1 participates in the development of progressive chronic kidney disease among patients with congestive heart failure

2021 ◽  
Vol 18 (1) ◽  
Author(s):  
Yingwei Chang ◽  
Chunmei Liu ◽  
Jing Wang ◽  
Jing Feng ◽  
Yulan Chen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Congestive Heart Failure ◽  
Kidney Disease ◽  
Roc Curve ◽  
Kidney Injury ◽  
Diagnostic Value ◽  
Curve Analysis ◽  
Roc Curve Analysis

Abstract Background Congestive heart failure (CHF) is a major cause of the development of progressive chronic kidney disease (CKD), while the mechanism is still unknown. LncRNA PVT1 contributes to kidney injury. This study aimed to explore the role of PVT1 in the development of CKD in CHF patients. Methods Expression of PVT1 in plasma samples of CHF patients with and without CKD was determined by RT-qPCR. The diagnostic value of plasma PVT1 for CKD was evaluated by ROC curve analysis. The predictive value of PVT1 for the development of CKD in CHF patients was analyzed by a 2-year follow-up study. Changes in PVT1 expression in CKD patients during treatment were analyzed by RT-qPCR and reflected by heatmaps. Results Plasma PVT1 was downregulated in CHF and further downregulated in CHF patients complicated with progressive CKD. ROC curve analysis showed that plasma PVT1 levels could be used to distinguish CHF patients complicated with CKD from CHF patients without CKD and healthy controls. During a 2-year follow-up, patients with high CHF levels had a low incidence of progressive CKD among CHF patients. Moreover, with the treatment of progressive CKD, plasma PVT1 was upregulated. Conclusions LncRNA-PVT1 downregulation may participate in the development of progressive CKD among patients with CHF.

scholarly journals Diagnostic Performance of Cortactin in the Diagnosis of Oral Squamous Cell Carcinoma

2020 ◽  
Author(s):  
Lili Wang ◽  
Hongguang Song ◽  
Shiming Yang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Mrna Expression ◽  
Squamous Cell ◽  
Roc Curve ◽  
Area Under The Curve ◽  
Diagnostic Value ◽  
Curve Analysis ◽  
Roc Curve Analysis

Abstract Background: Cortactin gene was up-regulated in various human cancers. However, the role of cortactin in the diagnosis of oral squamous cell carcinoma (OSCC) remained unclear. The aim of this study was to investigate the diagnostic value of cortactin in OSCC patients.Methods: The relative mRNA expression levels of cortactin in OSCC tissues and adjacent normal oral mucosal tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was used to analyze the correlation between cortactin expression and clinical characteristics of patients. The diagnostic value of cortactin in OSCC patients was estimated via receiver operating characteristic (ROC) curve analysis.Results: Compared with the normal controls, cortactin mRNA expression was significantly increased in OSCC tissues (P<0.001). Importantly, notable correlations were found between cortactin expression and tumor size (P=0.040), TNM stage (P=0.018), lymph node metastasis (P=0.013) as well as recurrence (P=0.031). Furthermore, the result of ROC curve analysis showed that the area under the curve (AUC) was 0.867 with a sensitivity of 76.2% and a specificity of 86.9%. It revealed that the diagnostic value of cortactin was high in OSCC patients.Conclusions: Our data reveal that cortactin expression is up-regulated in OSCC and correlated with tumor progression. Cortactin may be a potential bio-marker for early diagnosis of OSCC.

scholarly journals Diagnosis of Parapneumonia Pleural Effusion With Serum and Pleural Effusion Activin A

2021 ◽  
Author(s):  
Guanghui Zhou ◽  
Yi Shan ◽  
Zhiwei Tang ◽  
Ruhua Chen ◽  
Yan Fen ◽  
...  
Keyword(s):  
Pleural Effusion ◽  
Roc Curve ◽  
Operating Characteristic ◽  
Diagnostic Value ◽  
Activin A ◽  
Curve Analysis ◽  
Roc Curve Analysis ◽  
Reactive Protein ◽  
Diagnostic Potential ◽  
Parapneumonic Pleural Effusion

Abstract Background We aimed to evaluate the diagnostic value of Activin A levels in serum and pleural effusion on parapneumonic pleural effusion (PPE). Methods We collected serum and pleural effusion from 86 PPE and 37 non-PPE (NPPE) patients. Including Activin A, levels of biomarkers as lactate dehydrogenase (LDH), procalcitonin (PCT) and C-reactive protein (CRP) were measured. All factors were calculated for association with days after admission. The diagnostic potential of biomarkers on PPE was considered by receiver operating characteristic (ROC) curve analysis. Results Levels of Activin A in serum and pleural effusion of PPE patients were significantly higher than those of the NPPE patients. Moreover, concentrations of Activin A in pleural effusion showed a more obvious relevant days after admission. ROC curve analysis found that Activin A in pleural effusion had AUCs of 0.899 with 93% sensitivity and 84% specificity for PPE diagnosis. Conclusion Activin A in pleural effusion correlated with disease severity could act to diagnosis PPE.

scholarly journals Gene4PD: a comprehensive genetic database of Parkinson's disease

2020 ◽  
Author(s):  
Bin Li ◽  
Guihu Zhao ◽  
Qiao Zhou ◽  
Yali Xie ◽  
Zheng Wang ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Neurodegenerative Disorder ◽  
Late Onset ◽  
Permutation Test ◽  
Association Studies ◽  
Genetic Data ◽  
Genome Wide Association Studies ◽  
Onset Age ◽  
Loss Of Function

Abstract BackgroundParkinson's disease (PD) is a complex neurodegenerative disorder with a strong genetic component. A growing number of variants and genes have been reported to be associated with PD; however, there is no database that integrate different type of genetic data, and support analyzing of PD-associated genes (PAGs).MethodsBy systematic review and curation of multiple lines of public studies, we integrate multiple layers of genetic data (rare variants and copy-number variants identified from patients with PD, associated variants identified from genome-wide association studies, differential expression genes, and differential DNA methylation genes) and clinical data in PD. A weighted scoring system was employed to prioritize PAGs. Permutation test and protein-protein interaction network was used to evaluate the interconnectivity and functional correlation among the PAGs. The relationship between AAO and PAGs was further analyzed. A PHP-based web framework was used to construct a database. ResultWe integrated five layers of genetic data with different levels of evidences from more than 3,000 studies and prioritized 124 PAGs with strong or suggestive evidences. These PAGs were identified to be significantly interacted with each other and formed an interconnected functional network enriched in several functional pathways involved in PD, suggesting these genes may contribute to the pathogenesis of PD, which also highlighting the reliability of these genetic data for PD. Furthermore, we identified 10 genes were associated with a juvenile-onset (age ≤ 30 years), 11 genes were associated with an early-onset (age of 30–50 years), whereas another 10 genes were associated with a late-onset (age > 50 years). Notably, the AAOs of patients with loss of function variants in five genes (GCH1, PINK1, PRKN, FBXO7, ATP13A2) were significantly lower than that of patients with deleterious missense variants, while patients with VPS13C (P = 0.01) was opposite. Finally, we developed an online database named Gene4PD (http://genemed.tech/gene4pd) which integrated published genetic data in PD, the PAGs, and 63 popular genomic data sources, as well as an online pipeline for prioritize risk variants in PD.ConclusionGene4PD provides researchers and clinicians comprehensive genetic knowledge and analytic platform for PD, and would also improve the understanding of pathogenesis in PD.Availability and Implementation: Gene4PD can be freely accessed at http://genemed.tech/gene4pd.

scholarly journals Pareidolia in Parkinson’s Disease and Multiple System Atrophy

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Kentaro Kurumada ◽  
Atsuhiko Sugiyama ◽  
Shigeki Hirano ◽  
Tatsuya Yamamoto ◽  
Yoshitaka Yamanaka ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Sensitivity And Specificity ◽  
Trait Anxiety ◽  
Roc Curve ◽  
Visual Hallucinations ◽  
State Trait Anxiety Inventory ◽  
Roc Curve Analysis ◽  
Specific Test

Pareidolia is a visual illusion of meaningful objects that arise from ambiguous forms embedded in visual scenes. Previous studies showed that pareidolias are frequently observed in patients with Parkinson’s disease (PD) as well as dementia with Lewy bodies. However, whether pareidolias are useful for differentiating PD from other neurodegenerative parkinsonism disorders including multiple system atrophy (MSA) is unclear. The noise pareidolia test (NPT) was performed in 40 and 48 patients with PD and MSA, respectively. A receiver operating characteristic (ROC) curve analysis was used to evaluate sensitivity and specificity. Results of neuropsychological tests were also compared between patients with PD with and without pareidolias. Visual hallucinations were present in none of the subjects. Pareidolic response in the NPT was observed in 47.5% and 18.8% of patients with PD and MSA, respectively. The number of pareidolic responses in patients with PD was significantly larger compared with patients with MSA ( P = 0.001 ). ROC curve analyses showed the sensitivity and specificity at 33% and 98%, respectively. Among patients with PD, those with pareidolias demonstrated higher State-Trait Anxiety Inventory-state ( P = 0.044 ) and State-Trait Anxiety Inventory-trait ( P = 0.044 ) than those without pareidolias. Pareidolias can be found in patients with PD without visual hallucinations, and the pareidolia test may be a highly specific test for differentiating PD from MSA. Thus, anxiety may be associated with pareidolias in patients with PD.

scholarly journals Betatrophin Acts as a Diagnostic Biomarker in Type 2 Diabetes Mellitus and Is Negatively Associated with HDL-Cholesterol

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Min Yi ◽  
Rong-ping Chen ◽  
Rui Yang ◽  
Xian-feng Guo ◽  
Jia-chun Zhang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Roc Curve ◽  
Diagnostic Value ◽  
Curve Analysis ◽  
Newly Diagnosed ◽  
Diagnostic Biomarker ◽  
Roc Curve Analysis

Objective. By assessing its circulating concentrations in type 2 diabetes mellitus (T2DM) patients, we aimed to explore the associations of betatrophin with various metabolic parameters and evaluate its diagnostic value in T2DM.Methods. A total of 58 non-diabetes-mellitus (NDM) subjects and 73 age- and sex-matched newly diagnosed T2DM patients were enrolled. Correlation analyses between circulating betatrophin levels and multiple metabolic parameters were performed. Receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic value of betatrophin concentration in T2DM.Results. Circulating betatrophin levels were approximately 1.8 times higher in T2DM patients than in NDM individuals (median 747.12 versus 407.41 pg/mL,P<0.001). Correlation analysis showed that betatrophin was negatively associated with high-density lipoprotein cholesterol (HDL-C) levels in all subjects. ROC curve analysis identified betatrophin as a potent diagnostic biomarker for T2DM. The optimal cut-off point of betatrophin concentration for predicting T2DM was 501.23 pg/mL.Conclusions. Serum betatrophin levels were markedly increased in newly diagnosed T2DM patients and further elevated in obese T2DM subjects. Betatrophin was negatively correlated with HDL-C levels. Our findings indicate that betatrophin could be a potent diagnostic biomarker for T2DM.

Sign in / Sign up

Export Citation Format

Share Document